Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group.
Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Lindén O, Sundström C; Nordic Lymphoma Group. Kimby E, et al. Among authors: lehtinen t. Leuk Lymphoma. 2008 Jan;49(1):102-12. doi: 10.1080/10428190701704647. Leuk Lymphoma. 2008. PMID: 18203019 Clinical Trial.
T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.
Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E. Wahlin BE, et al. Among authors: lehtinen t. Clin Cancer Res. 2011 Jun 15;17(12):4136-44. doi: 10.1158/1078-0432.CCR-11-0264. Epub 2011 Apr 25. Clin Cancer Res. 2011. PMID: 21518780 Free article.
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. Pfreundschuh M, et al. Among authors: lehtinen t. Lancet Oncol. 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7. Lancet Oncol. 2006. PMID: 16648042 Clinical Trial.
Atopy and risk of non-Hodgkin lymphoma.
Melbye M, Smedby KE, Lehtinen T, Rostgaard K, Glimelius B, Munksgaard L, Schöllkopf C, Sundström C, Chang ET, Koskela P, Adami HO, Hjalgrim H. Melbye M, et al. Among authors: lehtinen t. J Natl Cancer Inst. 2007 Jan 17;99(2):158-66. doi: 10.1093/jnci/djk019. J Natl Cancer Inst. 2007. PMID: 17227999
Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.
Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, Haapasaari KM, Leppä S, Mannisto S, Karjalainen-Lindsberg ML, Lehtinen T, Eray M, Vornanen M, Haapasalo H, Soini Y, Jantunen E, Nousiainen T, Vasala K, Kuittinen O. Harjama L, et al. Among authors: lehtinen t. Acta Oncol. 2015 Jun;54(6):939-43. doi: 10.3109/0284186X.2014.990110. Epub 2015 Mar 11. Acta Oncol. 2015. PMID: 25761092
Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003.
Jantunen E, Itälä M, Siitonen T, Koivunen E, Leppä S, Juvonen E, Kuittinen O, Lehtinen T, Koistinen P, Nyman H, Nousiainen T, Volin L, Remes K. Jantunen E, et al. Among authors: lehtinen t. Eur J Haematol. 2006 Aug;77(2):114-9. doi: 10.1111/j.1600-0609.2006.00685.x. Eur J Haematol. 2006. PMID: 16856906
106 results